India’s Lupin Plans Expansion Into Cardiology, Neurology Generics
This article was originally published in PharmAsia News
Executive Summary
Lupin Laboratories, ranked fifth in size of Indian drug makers, plans to expand its formulations business so it can move into new generics markets in the country. The new focus areas for Lupin are cardiology and neurology, building on its recent expansion into cancer care and diabetes formulations. The entry into oncology drugs was launched last quarter. (Click here for more